Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 16/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23907536 | 0.99 | NT5E (0.47) | CTSLCTSSCTSKNT5EADORA1 | |
| SCHEMBL23907430 | 0.98 | NT5E (0.45) | CTSLCTSSCTSKNT5EADORA1 | |
| SCHEMBL23907546 | 0.93 | NT5E (0.41) | CTSLCTSSCTSKNT5EADORA1 | |
| SCHEMBL23907534 | 0.92 | NT5E (0.46) | NT5EADORA1ADORA3ADORA2ATAS1R3 | |
| SCHEMBL23907405 | 0.91 | NT5E (0.42) | CTSLCTSSCTSKNT5EADORA1 | |
| SCHEMBL23907390 | 0.90 | ADORA1 (0.45) | NT5EADORA1ADORA3ADORA2ATAS1R3 | |
| SCHEMBL23907422 | 0.90 | ADORA1 (0.43) | NT5EADORA1ADORA3ADORA2ATAS1R3 | |
| SCHEMBL23907514 | 0.90 | ADORA1 (0.48) | NT5EADORA1ADORA3ADORA2ATAS1R3 | |
| SCHEMBL23907537 | 0.90 | NT5E (0.45) | NT5EADORA1ADORA3ADORA2ATAS1R3 | |
| SCHEMBL23907488 | 0.89 | ADORA3 (0.57) | NT5EADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | ENTPD5, ENTPD1, ENTPD3 | CTSL 1567/4885CTSS 965/4885CTSK 1117/4885 |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | CTSL 1251/4885CTSS 854/4885CTSK 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.